# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc ...
Stephens & Co. analyst Mason Carrico reiterates Guardant Health (NASDAQ:GH) with a Overweight and maintains $44 price ta...
FDA panel recommends approval for Guardant Health's Shield blood test for colorectal cancer screening.
MRUS: 23% | Merus shares are trading higher after the company announced the publication of an abstract regarding petosemtamab i...